• In late May and early June 2026, Corcept Therapeutics reported strong overall survival data for newly approved ovarian cancer drug Lifyorli from its Phase 3 ROSELLA trial at ASCO, while also disclosing that the U.S. Department of Justice declined to intervene in a long-running qui tam lawsuit related to Korlym’s promotion and reimbursement.
• Beyond reinforcing Lifyorli’s clinical profile and guideline inclusion, these updates highlight Corcept’s evolution from a single-product Cushing’s syndrome focus toward a broader glucocorticoid receptor–targeted oncology and endocrine portfolio.
• We’ll now examine how Lifyorli’s ROSELLA survival data and recent FDA approval shape Corcept’s investment narrative and future growth drivers.

Capitalize on the AI infrastructure supercycle with our selection of the 48 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

What Is Corcept Therapeutics' Investment Narrative?

To own Corcept today, you need to believe in its shift from a Korlym-centric story to a diversified glucocorticoid receptor platform anchored by Lifyorli in ovarian cancer and a potential second act for relacorilant in Cushing’s. The ROSELLA survival data and NCCN “preferred” status reinforce Lifyorli’s clinical relevance and help explain the sharp share price move in recent months, while also strengthening one of the key near-term catalysts: uptake of the new regimen off a growing revenue base that management now guides to US$950 million to US$1.05 billion in 2026. On the risk side, the DOJ’s decision not to intervene in the Korlym qui tam case removes an overhang, but securities litigation around the relacorilant CRL, higher R&D spend and a swing to a Q1 loss keep execution and legal outcomes firmly in focus.

However, one legal and regulatory thread here could matter more than many investors realise. Corcept Therapeutics' shares have been on the rise but are still potentially undervalued by 13%. Find out what it's worth.

Exploring Other Perspectives

Community members on Simply Wall St have published five fair value estimates for Corcept, spanning roughly US$83.61 to US$168.50 per share, so you see very different views of upside. Set that against the current focus on Lifyorli’s launch, relacorilant’s resubmitted Cushing’s filing and ongoing lawsuits, and it becomes clear why taking in multiple perspectives can be useful before deciding how Corcept fits into your portfolio.

Explore 5 other fair value estimates on Corcept Therapeutics - why the stock might be worth just $83.61!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Corcept Therapeutics research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Corcept Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Corcept Therapeutics' overall financial health at a glance.

Contemplating Other Strategies?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
• AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Outshine the giants: these 13 early-stage AI stocks could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.